Skip to main content

MapLight Therapeutics, Inc.

corporate_fare Company Profile

MapLight Therapeutics, Inc.

MPLT·NASDAQ·Life Sciences·CIK 0001770069

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform aims to identify neural circuits causally linked to disease and target those circuits for therapeutic modulation. Our lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC). We are initially developing ML-007C-MA for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP). This candidate is designed to activate both M1 and M4 muscarinic receptors centrally to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. ML-007, either alone, co-administered, or co-formulated with PAC, has been evaluated in four Phase 1 trials, involving a total of 270 healthy participants and more than 1,500 doses of ML-007 administered. We are currently conducting ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for the treatment of schizophrenia. We expect this trial to reach its target enrollment of 300 participants in April 2026 and report topline results in the third quarter of 2026. Additionally, we are conducting VISTA, a Phase 2 trial evaluating ML-007C-MA for the treatment of ADP, and expect to report topline results in the second half of 2027.

MapLight Therapeutics, Inc. (NASDAQ:MPLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for MPLT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • MapLight Therapeutics Reports Widened Q1 Net Loss and Doubled Operating Cash Burn, Confirms Runway Through 2027
  • MapLight Therapeutics Completes Enrollment for Two Phase 2 Trials, Reports Q1 Results
  • MapLight Therapeutics Reports 2025 Annual Results, Extends Cash Runway to 2027, and Details Pipeline Progress
  • MapLight Therapeutics Reports Strong Cash Position & Key Clinical Milestones, Including Two Phase 2 Readouts in Q3 2026
  • MapLight Therapeutics Nears Key Phase 2 Readouts in Q3 2026, Extends Cash Runway Through 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$161.15M
Diluted EPS
-$18.56
Op. Cash Flow
-$138.14M
Free Cash Flow
-$138.61M
Operating Income
-$169.08M
Cash & Equivalents
$46.73M
Debt / Equity
0.00×
Shares Outstanding
44.02M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-125072
$5.94
52-week range · as of 2026-11-16 $5.94 – $40.43
Market cap
$330.12M
Volume
357.9K (1.0× avg)
3-mo avg 375.2K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MPLT - Filings & News (Page 2)

MPLT
May 14, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.29
Real-time Price: $5.94 info
Change: -$23.35 (-80%) info
Market Cap: $330.12M info
MPLT
May 14, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.29
Real-time Price: $5.94 info
Change: -$23.35 (-80%) info
Market Cap: $330.12M info
MPLT
Mar 26, 2026, 7:20 AM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $17.50
Real-time Price: $5.94 info
Change: -$11.56 (-66%) info
Market Cap: $330.12M info
MPLT
Mar 26, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.14
Real-time Price: $5.94 info
Change: -$12.20 (-67%) info
Market Cap: $330.12M info
MPLT
Mar 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.14
Real-time Price: $5.94 info
Change: -$12.20 (-67%) info
Market Cap: $330.12M info
MPLT
Jan 09, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.19
Real-time Price: $5.94 info
Change: -$11.25 (-65%) info
Market Cap: $330.12M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets